CLDX Q1 2023 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$967,000+455.7% YoY

Gross Profit

-$26M-2671.3% margin

Operating Income

-$32M-3357.9% margin

Net Income

-$29M-3036.3% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-40.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$325M

Total Liabilities

$22M

Stockholders' Equity

$303M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$967,000	$174,000	+455.7%
Gross Profit	-$26M	-$17M	-53.0%
Operating Income	-$32M	-$23M	-39.6%
Net Income	-$29M	-$23M	-27.4%

Revenue Segments

Grant

$967,000100%